Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × magrolimab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Myeloid Malignancies 1 Multiple Myeloma 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1 Colorectal Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Bevacizumab 206 Fluorouracil 198 Irinotecan 192 Oxaliplatin 189 Leucovorin 178 Capecitabine 132 Cetuximab 128 Panitumumab 62 Folfox protocol 45 regorafenib 39 Radiotherapy 36 IFL protocol 35 pembrolizumab 34 HMPL-013 30 trifluridine tipiracil drug combination 28 Nivolumab 27 Neoadjuvant Therapy 23 Drug Therapy 21 tislelizumab 16 Celecoxib 16 aflibercept 15 XELOX 15 Trifluridine 14 Chemotherapy, Adjuvant 14 sintilimab 13 atezolizumab 13 Trastuzumab 13 Gemcitabine 13 durvalumab 12 apatinib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05330429 2025-07-01

ELEVATE CRC

Gilead Sciences

Phase 2 Terminated

77 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡